Detalhe da pesquisa
1.
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Blood
; 139(11): 1684-1693, 2022 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34614146
2.
High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Blood
; 135(16): 1396-1405, 2020 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31978225
3.
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
Cancer
; 125(13): 2291-2299, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30901086
4.
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Lancet
; 388(10044): 565-75, 2016 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27313086
5.
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Br J Haematol
; 174(5): 692-9, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27118109
6.
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Haematologica
; 101(4): 474-81, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26721893
7.
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
Am J Hematol
; 91(11): 1096-1101, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27465588
8.
Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Hematol Oncol
; 33(1): 1-8, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24496668
9.
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Haematologica
; 99(7): 1236-8, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24727820
10.
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma.
Oncologist
; 18(11): 1189, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24105750
11.
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Blood
; 117(6): 2009-11, 2011 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20962323
12.
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.
Blood
; 117(11): 3041-4, 2011 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-21098740
13.
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Blood
; 118(22): 5752-8; quiz 5982, 2011 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21849487
14.
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Haematologica
; 98(7): 1107-14, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23645690
15.
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Haematologica
; 98(11): 1726-31, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23753028
16.
Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients.
Hematol Oncol
; 31(2): 57-64, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22886543
17.
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.
Am J Hematol
; 88(3): 207-12, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23335406
18.
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Lancet
; 377(9759): 42-51, 2011 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21176949
19.
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Blood
; 116(12): 2040-5, 2010 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-20548096
20.
Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.
Hematol Oncol
; 29(1): 10-6, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21381074